You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

11 Results
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Hodgkin
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Drugs Used:
vinCRIStine,
procarbazine,
prednisone,
DOXOrubicin,
cyclophosphamide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2019
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Obinutuzumab - Maintenance Treatment for Refractory Follicular Lymphoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
oBINutuzumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Dec 2019
Guidelines and Advice
Status: Current
ID: GL 5-3ORG
Version: 2
Apr 2019
Guidelines and Advice
Status: Current
Version: N/A
Aug 2019
Guidelines and Advice
Status: Current
ID: 21-4
Version: N/A
Aug 2019
Guidelines and Advice
Status: Current
ID: N/A
Version: N/A
Oct 2019
Drug
Other Name(s): Lynparza®
Quick Link(s): Drug Monograph, Patient Info Sheet
Jan 2025
Guidelines and Advice
Status: Current
Updated
Mar 2025
Guidelines and Advice
Updated
Mar 2025
Guidelines and Advice
Status: Current
Updated
Mar 2025
Statistical Reports
Ontario Cancer Statistics 2024 is the fifth in a series of reports that provide comprehensive information on the burden of cancer in Ontario....
New
Feb 2025